PD-L1 expression and response to nivolumab in a case of relapsed/refractory lymphomatoid granulomatosis

Jonathan Weiss, Tera Mayer, Noah Brown, Ryan A. Wilcox

Abstract

A 54 years old gentleman presented with lymphomatoid granulomatosis (LyG), an EBV-driven lymphoproliferative disorder associated with angiocentric invasion and expansion of EBV positive B cells. He ultimately developed biopsy-confirmed recurrent disease, despite treatment with immunochemotherapy. A biopsy demonstrated PD-L1 expression, and he underwent treatment with nivolumab, achieving a complete response. Our experience further supports ongoing clinical trials investigating PD-L1/PD-1 blockade in LyG and EBV-associated lymphomas.